|
|||||||||||||||||||
|
|
|
Cubist
Pharmaceuticals, Inc. (CBST) was a biopharmaceutical company focused
on the discovery, development and commercialization of innovative
antibiotics for the treatment of serious and life-threatening
infections. The company was founded in 1992 and was headquartered in
Lexington, Massachusetts. In December 2014, CBST was acquired by Merck & Co., Inc. for $9.5 billion. At the time of the acquisition, CBST had several marketed products including Cubicin and Zerbaxa, as well as a robust pipeline of antibiotic candidates in development. Cubicin was a lipopeptide antibiotic used to treat a variety of skin and bloodstream infections caused by Gram-positive bacteria. Zerbaxa was a combination of ceftolozane and tazobactam used to treat complicated urinary tract and intra-abdominal infections caused by Gram-negative bacteria. The acquisition of CBST by Merck was part of a larger trend in the pharmaceutical industry of consolidation through mergers and acquisitions. Merck saw CBST as a strategic fit to expand its pipeline of antibiotics and strengthen its position in the infectious disease market. In addition to its antibiotics, CBST was also a leader in the development of diagnostic tests for bacterial infections, including the Xpert MRSA/SA Blood Culture test, which was used to detect MRSA and other Staphylococcus infections in blood samples. Overall, CBST was an important player in the fight against antibiotic-resistant infections and its acquisition by Merck has helped to strengthen the development of new antibiotics and diagnostic tools for infectiou
|
||||||||||||
|
||||||||||||
|
Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy |
Refund Policy | Disclaimer